Clinical effect of the combination of compound Kushen injection and gemcitabine on postoperative patients with non-muscle invasive bladder cancer and its influence on serum-related factors

• Xuena Dong ^[1] ; Yuhan Wang ^[2] ; Shuhui Wang ^[3] ; Cong Li ^[4] ; Min Zhang ^[5] ; Fanglin Hou ^[6]
  1. [1] Department of Surgery Outpatient, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
  2. [2] Department of Critical Care Medicine, Affiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital, Qingdao, Shandong, China
  3. [3] Department of Clinical Laboratory, Affiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital, Qingdao, Shandong, China
  4. [4] E.N.T. Department (I), Jinan Zhangqiu District People’s Hospital, Jinan, Shandong, China
  5. [5] Department of Health Management, Jinan Zhangqiu District People’s Hospital, Jinan, Shandong, China
  6. [6] Department of Outpatient, Qingdao Hiser Hospital Affiliated of Qingdao University (Qingdao Traditional Chinese Medicine Hospital), Qingdao, Shandong, China

  Mostrar afiliaciones +
• Localización: Archivos españoles de urología, ISSN 0004-0614, Tomo 76, Nº. 9, 2023, págs. 657-665
• Idioma: español
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective: To observe the clinical effect of the combination of compound Kushen injection (CKI) and gemcitabine on postoperative patients with non-muscular invasive bladder cancer (NMIBC) and its influence on serum-related factors.

    Methods: A total of 150 patients with NMIBC were randomly divided into two groups. The patients in the control group (n = 75) received gemcitabine therapy; They were given 0.2 g gemcitabine once a week for 8 weeks after surgery and then changed to once every 2 weeks for eight times. The patients in the observation group (n = 75) were given CKI treatment on the basis of the control group for 10 days. The treatment was continued for three courses. After continuous follow-up for 2 years, the blood biochemistry, serum-related factors and immune T cell subsets and the safety and immune function changes, total effective rate, recurrence rate and occurrence of adverse reactions were evaluated.

    Results: The interferon-γ, interleukin (IL)-2, clusters of differentiation (CD)8+, serum cell adhesion molecules (CAMs), hepatocyte CAM and cysteine proteinase-8 levels in the two groups after treatment significantly increased compared with those before treatment (p < 0.05), with the observation group showing more increase (p < 0.05). However, the tumour necrosis factor-α, C-reactive protein (CRP), IL-6, CD3+, CD4+, matrix metalloproteinase (MMP)-9, MMP-2, epithelial-specific CAM, soluble CAM-1, liver CAM, E-cadherin, vascular endothelial growth factor and fibroblast growth factor levels decreased significantly after treatment (p < 0.05), with the observation group exhibiting more decrease (p < 0.05). The adverse reactions and recurrence rate in the observation group obviously decreased in comparison to those in the control group (p < 0.05).

    Conclusions: The combination of CKI and gemcitabine can improve the inflammatory response, relieve the clinical symptoms of patients and reduce adverse clinical symptoms during gemcitabine infusion chemotherapy, with high safety.